AOCOPM 2023 Midyear Educational Conference-259668

Video Transcription

Video Summary

The presentation featured Dr. Philip Eskew discussing the evolution and challenges of addiction treatment within correctional medicine. With broad expertise in direct primary care and correctional healthcare, Dr. Eskew addressed the impact of addiction on incarcerated populations, noting the high rates of substance use disorders in these settings. He outlined the current treatment options for opioid use disorders, including buprenorphine, methadone, and naltrexone, emphasizing that correctional facilities must offer all three to comply with ADA requirements. Dr. Eskew also discussed the shift toward microdosing buprenorphine to avoid the complications of traditional withdrawal management strategies and highlighted the significant reduction in recidivism rates when medication-assisted treatment is used.<br /><br />The talk covered the nuances of dealing with multiple substance use disorders, the importance of careful patient monitoring during withdrawal, and the legal implications of failing to treat addiction as a disability under the ADA. Additionally, Dr. Eskew addressed the socio-economic factors affecting the feasibility of long-term addiction treatments in correctional facilities, with a focus on integrating community care post-release to prevent relapse and overdose.

Keywords

addiction treatment

correctional medicine

substance use disorders

opioid use disorders

medication-assisted treatment

ADA compliance

microdosing buprenorphine

recidivism reduction

community care integration